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Background: The genetic basis for avian to mammalian host switching in influenza A virus is largely unknown. The
human A/HK/156/1997 (H5N1) virus that transmitted from poultry possesses NS1 gene mutations F103L + M106I
that are virulence determinants in the mouse model of pneumonia; however their individual roles have not been
determined. The emergent A/Shanghai/patient1/2013(H7N9)-like viruses also possess these mutations which may
contribute to their virulence and ability to switch species.
Methods: NS1 mutant viruses were constructed by reverse genetics and site directed mutagenesis on human and
mouse-adapted backbones. Mouse infections assessed virulence, virus yield, tissue infection, and IFN induction. NS1
protein properties were assessed for subcellular distribution, IFN antagonism (mouse and human), CPSF30 and RIG-I
domain binding, host transcription (microarray); and the natural prevalence of 103L and 106I mutants was assessed.
Results: Each of the F103L and M106I mutations contributes additively to virulence to reduce the lethal dose
by >800 and >3,200 fold respectively by mediating alveolar tissue infection with >100 fold increased infectious
yields. The 106I NS1 mutant lost CPSF binding but the 103L mutant maintained binding that correlated with an
increased general decrease in host gene expression in human but not mouse cells. Each mutation positively
modulated the inhibition of IFN induction in mouse cells and activation of the IFN-β promoter in human cells but
not in combination in human cells indicating negative epistasis. Each of the F103L and M106I mutations restored a
defect in cytoplasmic localization of H5N1 NS1 in mouse cells. Human H1N1 and H3N2 NS1 proteins bound to the
CARD, helicase and RD RIG-I domains, whereas the H5N1 NS1 with the same consensus 103F and 106M mutations
did not bind these domains, which was totally or partially restored by the M106I or F103L mutations respectively.
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Conclusions: The F103L and M106I mutations in the H5N1 NS1 protein each increased IFN antagonism and
mediated interstitial pneumonia in mice that was associated with increased cytoplasmic localization and altered
host factor binding. These mutations may contribute to the ability of previous HPAI H5N1 and recent LPAI H7N9
and H6N1 (NS1-103L+106M) viruses to switch hosts and cause disease in humans.
Keywords: NS1, Nonstructural protein 1, Influenza A virus, Host switch, Nuclear, Cytoplasmic localization, Nuclear
export signal, Host gene expression, Virulence, Interferon, H7N9, H5N1, H6N1, Alveoli, tropismIntroduction
The 1997 highly pathogenic avian influenza (HPAI)
H5N1 (prototype A/HK/156/1997 (H5N1)) and 2013
low pathogenic avian influenza (LPAI) H7N9 (prototype
A/Shanghai/patient 1/2013 (H7N9)) lineages of influenza
A virus (IAV) have both acquired all 6 of their internal
protein encoding genome segments including the NS1
gene through reassortment with the A/Beijing/1/1994
(H9N2) (BJ1994) lineage of viruses in China [1-3]; and
both cause fatal interstitial pneumonia in humans [4-6].
Early and recent isolates of the LPAI H9N2 lineage
viruses are pathogenic for mice without adaptation [7-9]
and have directly infected humans in 1999 in Hong
Kong (see [10]). Although the majority of human cases
of H5N1 and H7N9 avian IAV are associated with direct
contact with infected poultry, without sustained human-
to-human transmission, they continue to pose a pan-
demic threat [11]. The scope and nature of this threat is
undefined because the genetic basis for host switching
and virulence is largely unknown. The evolution of an
engineered H5N1 IAV laboratory strain on serial nasal
passage in ferrets that is capable of airborne-transmission
after acquiring 5 mutations [12] suggests that further
adaptation in humans may generate a transmissible form
of human H5N1 or possibly H7N9. It is therefore neces-
sary to determine the genetic determinants of H9N2 IAV
origin genes in virulence that are relevant to interspecies
transmission.
In this paper we address the characterization of func-
tional determinants of virulence in the 1997 H5N1 NS1
gene that contribute to host switching and virulence.
We have previously shown that the pair of mutations,
F103L + M106I, in the A/Hong Kong/156/1997 (H5N1)
NS1 gene (H5N1-NS1) controlled virulence on the A/
PR/8/1934 (H1N1) (PR8) virus backbone [13]; (where
PR8 has the structural protein functions required to in-
fect alveoli and cause interstitial pneumonia [14]). F103L
and M106I mutations have been independently selected
in mammals, on mouse adaptation of human A/HK/1/
68 (H3N2) (HK) virus, and shown to possess adaptive
gain-of-function properties in vitro (transcription and
replication) and in vivo (increased virulence and IFN an-
tagonism in the mouse lung) but with reduced ability to
bind the cleavage and polyadenylation specificity factor30Kd subunit (CPSF30) [15]. The role of the NS1 103L
and 106I mutations relative to the consensus residues
103F and 106M is controversial because other studies
have shown reduced virulence associated with a loss of
ability to bind CPSF and antagonize IFN induction in A/
HK/483/1997 (H5N1) [16], in contrast to the same mu-
tations in the A/HK/156/1997 (H5N1) NS1 gene on the
PR8 backbone that increases IFN antagonism and repli-
cation associated with increased virulence [13]. Thus
these mutations appear to be subject to epistasis where
their phenotypes are dependent on the presence of other
mutations, as has been shown to be prevalent in IAV
surface proteins [17,18] and reported in the NP gene
[19]. This is consistent with evolutionary studies of RNA
viruses which show that their genetically simple and
compact genomes demonstrate extensive interactions, or
epistasis among and within multifunctional proteins,
where one mutation may enhance one function to the
detriment of another function but which is dependent
on other mutations (reviewed [20]). For example HIV
protease gene inhibitor resistant mutants acquire muta-
tions sequentially and in defined orders, where the first
confers drug resistance and subsequent mutations com-
pensate for side-effects of the first mutations but which
are deleterious when analyzed in isolation [21]. Conse-
quently, it is necessary to consider the effects of genomic
context when studying viral evolution.
A major function of NS1 is its involvement in modu-
lating multiple host responses including antagonism of
the type I IFN response (reviewed [22]). This is achieved
through interfering with pathogen associated molecular
pattern (PAMP) receptor interactions. NS1 binds the
viral PAMPS, dsRNA and ssRNA, [23,24] to block rec-
ognition and signaling by cytoplasmic retinoic inducible
gene (RIG-I) and surface expressed toll-like receptors
(TLR-3 and TLR-7) [25-27]. NS1 therefore blocks IFN
induction at the pre-transcriptional level to prevent activa-
tion of the transcription factors IRF-3, IRF-7, ATF-2/c-Jun
and NF-κB that signal IFN induction [28-30]. Another
strategy employed by NS1 is the direct binding to RIG-I
[31] as well as TRIM25 [32] and RIPLET (human and
mouse RIG-I E3 ubiquitin ligases respectively) resulting in
inhibition of the RIG-I/IPS-1 mediated activation of IRF-3
and NF-κB [33]. Mouse cells lack TRIM25 interaction but
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ubiquitination and signaling by RIG-I [34]. The A/WSN/
1933 NS1 protein has been shown to bind the CARD and
regulatory domain (RD) of RIG-I but not the helicase do-
main in a bacterial reverse two hybrid assay (RTHS) [35].
NS1 inhibits the 3′-end processing of host mRNAs,
including IFN-β and IFN responsive genes, by binding to
the CPSF30-F2F3 (F2F3 zinc finger domain of CPSF-30)
[36,37], PABPNI [38] and U6 snRNA [39], therefore
down regulating host mRNA splicing and maturation.
In addition to preventing the maturation of the poly-
adenylated cellular mRNAs, NS1 also sequesters them
in the nucleus by directly binding of mRNA [40,41] or
indirectly via mRNA protein factor binding [38,42].
NS1 blocks IFN induced signalling functions in the
cytoplasm [43] and cytoplasmic IFN effectors, 2′-5′
OAS and PKR to support viral gene expression [44-46].
Mutations at positions 103 and 106 in PR8 NS1, (F103S
and M106I), have been shown to function to increase
cytoplasmic localization in MDCK cells, which may con-
tribute to increased cytoplasmic functioning [47].
NS1 uses the host translation machinery to select-
ively enhance viral protein translation and therefore
replication [48,49]. NS1 F103L and M106I mutations
also increase viral RNA polymerase activity in the lu-
ciferase mini-genome assay and increase transcription
in infected mouse cells [15]. NS1 has also been shown
to interact with all IAV proteins including all 3 viral
polymerase subunits in 2-hybrid assays [50]; and host
RNA helicase A (RHA) to enhance viral polymerase
activity [51].
IAV virulence is multigenically controlled [52,53]; how-
ever genetic studies have identified specific NS1 residues
with virulence. Previous studies of pathogenic avian A/
HK/156/97 H5N1 showed that the NS1 gene mediated in-
creased virulence in the mouse [54] and swine models
[55] when analyzed on the PR8 backbone. Furthermore
other studies of virulence identified single mutations in
the NS1 gene (P42S, D92E and V149A) as well as mul-
tiple mutations in the PDZ ligand domain that in-
creased virulence, replication and reduced IFN protein
levels [55-58]. A naturally occurring 5 aa deletion of
NS1 residues 191–195 of H5N1 swine viruses contrib-
uted to reduced pathogenicity in mice and chicken that
was associated with reduced NS1-CPSF30 binding and
IFN antagonism [59].
In this paper we demonstrate the ability of both the
F103L and M106I mutations to increase replication, al-
veolar tropism and virulence in the poultry adapted hu-
man isolate A/HK/156/97 (H5N1) NS1 gene on the PR8
backbone. We show that each of these mutations in-
creases cytoplasmic localization in mouse cells but that
they differ in their effects on binding to the CPSF30 as
well as human RIG-I domains.Materials and methods
Cells
Mardin-Darby canine kidney (MDCK) cells, human em-
bryonic kidney cells (293T), monkey kidney cells (Vero)
and mouse kidney epithelial cells (M1) were maintained
as described previously [53].
Viruses
Recombinant influenza viruses on the A/PR/8/1934
(H1N1) or A/HK/1/68 (H3N2) backbone were synthe-
sized by reverse genetics as previously described [60,61].
The NS genes of A/Hong Kong/156/97 (H5N1) (A/HK/
156/97) (Genbank AF036360) (synthesized by Biomatic
Corporation, Cambridge, Ontario) and A/HK/1/68 (H3N2)
were cloned into the pLLB(A) bidirectional vector by
homologous recombination as described [60,61]. The
A/Puerto Rico/8/34 (A/PR/8/34) NS gene and genome
in the pHW2000 bidirectional plasmid was obtained
from R. Webby, (St. Jude Children’s Research Hospital,
Memphis). Site directed mutagenesis was achieved by
polymerase chain reaction to introduce point mutations
into the A/HK/1/68 (H3N2), A/PR/8/34 (H1N1) and
H5N1 NS genes by using the primer pairs indicated in
Additional file 1: Table S1 using 50 ng of the each NS
gene of interest and the following conditions: 1 cycle
(98°C for 30 sec), 30 cycles (98°C for 10 sec, 52°C for
30 sec, 72°C for 2 min 30 sec) and 1 cycle (72°C for
8 min). PCR products were treated with 1 unit of the
Dpn1 (New England BioLabs, Pickering, ON) for 1 hour
at 37°C to remove the input plasmid. Each of the NS
plasmid constructs along with the 7 plasmids encoding
the viral structural genes of A/PR/8/34 (H1N1) or A/
HK/1/68 (H3N2) in pLLB were used to generate recom-
binant viruses as previously described [13,15]. The NS
gene sequence of the rescued viruses was verified by
sequence analysis. Viruses were grown in 10 day old
specific pathogen free (SPF) embryonated chicken eggs
(Canadian Food Inspection Agency, Ottawa, Ontario).
Viruses were titrated by plaque assay in MDCK cells as
described previously [13].
CPSF-30 F2F3-FLAG expression plasmid
Synthesis of the CPSF-30 F2F3-FLAG tagged fragment
clone in the pET17 vector under the control of the T7
promoter was previously described [15].
Assessment of replication of viruses in mouse lungs
Groups of 19–21 gram, female, Swiss-Webster CD-1 mice
(from Charles River Laboratories, Montreal, Quebec,
Canada) were infected intranasally under halothane
anesthesia with 5 × 103 pfu of each of the viruses in a vol-
ume of 50 μl [62]. CD-1 mice were sacrificed at 1, 3, 5 and
7 days post infection (dpi) and lungs from three mice were
collected for each day. Organs were weighed, diluted 1:4
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200, Retsch, Germany) for quantification by plaque assay.
Assessment of replication of viruses in cells
M1 cells were infected in triplicate with the indicated vi-
ruses at moi = 2 with sampling of supernatant to mea-
sure IFN-β and infectious yield at 24 hpi by ELISA and
plaque assay, respectively, in duplicate as described pre-
viously [13]. Vero cells were similarly infected in tripli-
cate at moi = 0.01 with analysis of virus yield by plaque
assay at 24 and 48 hpi, but with 0.5 μg TPCK trypsin/ml
in the medium.
Mouse survival assay
Groups of 5 female, 19-21 g, BALB/c or Swiss-Webster
(CD-1) mice were infected intranasally with 50 μL of de-
fined virus dosages under halothane anesthesia. Mortal-
ity was monitored for 10 dpi. Body weight was recorded
daily and the LD50 was calculated by the Karber-
Spearmen method [63].
Animal ethics approval
This study was carried out in accordance and compliance
with the guidelines of the Canadian Council on Animal
Care (CCAC) as described earlier [15]. The protocol was
approved by the University of Ottawa Animal Care Com-
mittee (Protocol Number: BMI-85).
Immunofluorescence staining of CD-1 lungs
CD-1 mice were infected intranasally with 1 × 105 pfu of
each of the recombinant viruses and lungs were col-
lected 3 dpi respectively. Lungs were inflated and fixed
with 3.7% formaldehyde and frozen sections were
stained as described previously [13]. Following washing,
the slides were incubated with 100 μl of the primary
rabbit anti-PR8 antibody (pre-adsorbed with mouse lung
extract, used at 1:500) at 4°C overnight. Images were
taken at 20× magnification using an Olympus BX50
microscope and processed in a parallel manner using
Photoshop 7.0.
Luciferase assay
The reporter plasmids expressing firefly luciferase under
the control of IFN-β (p125) and IRF-3 human promoters
(p55C1B) (Obtained from Yan Zhou, University of
Saskatchewan) were used to measure the relative ability
of NS1 proteins to suppress transfection-induced IFN-β
and IRF-3 promoted luciferase induction. A second re-
porter plasmid expressing Renilla luciferase under the
control of the constitutive simian virus 40 promoter (pRL-
SV40) was included as an internal transcription control.
Plasmid transfections (n=3) were performed in 293-T hu-
man embryonic kidney cells as previously described [53].
Briefly, 20 ng of firefly reporter plasmids, 20 ng of pLLBNS (or empty pLLB vector as a negative control) plasmids
and 10 ng of the internal control pRL-SV40 were mixed
with lipofectamine 2000 transfection reagent (Invitrogen,
Burlington, Ontario) and incubated for 30 min at RT be-
fore application to wells in a 96 well poly-D-lysine-treated
plates. Sixteen hours post transfection, the previous trans-
fection mix on cells was removed and the cells were
transfected with 1.0 ug of synthetic analog of dsRNA,
polyinosine-polycytosine (Poly I:C) (Amersham Pharmacia
Biotech) to induce the IFN-β promoter. At 40 h post-
transfection, luminescence was measured according to the
Promega Dual-Glo Luciferase Assay System protocol,
using a Glomax Multi-Detection System Model 9301–010
(Fisher Scientific, Nepean, Ontario). Relative luciferase
activities were calculated as the average +/− standard
deviation of the ratios of firefly and renilla luciferase lumi-
nescence for three biological replicates. Uniform NS1 pro-
tein expression was demonstrated by western blot for NS1
and actin as described previously [10].
NS1-CPSF30-F2F3 binding
The NS1 and CPSF-30-F2F3 expression and binding as-
says were performed as described previously [15]. The
H5N1-NS-103L+106I (wt) plasmid as well as the mu-
tants H5N1-NS-L103F+106I, H5N1-NS-103L+I106M and
H5N1-NS-L103F+I106M gene segments were cloned in
the pLLB vectors under the control of the T7 promoter.
Briefly, 0.5 μg of the various NS plasmids as well as
FLAG-tagged CPSF-F2F3 (FLAG-F2F3) fragment were
expressed in vitro using TnT T7 Quick-Coupled Tran-
scription/Translation System (Promega) in the presence of
10 μCi 35S-methionine and cysteine (Express 35S Protein
Labeling Mix, Perkin Elmer). In an α-FLAG pulldown
assay, equal volume of the in vitro translated and 35S-
labeled H5N1-NS and the three mutant NS proteins were
mixed with FLAG-F2F3 or H2O as a control (Additional
file 1: Figure S2) and precipitated using Protein G Dyna-
beads (Invitrogen, Burlington, Ontario) pre-incubated with
α-FLAG M2 antibody (Sigma, St Louis, Missouri). Follow-
ing washing beads were analyzed by SDS-PAGE electro-
phoresis and autoradiography.
NS1 protein localization
Monolayers of M1 cells were infected with the rPR8-
H5N1-NS-103L+106I (n=3) as well as the three mutants
(rPR8-H5N1-NS-L103F+106I, rPR8-H5N1-NS-103L+I106M
and rPR8-H5N1-NS-L103F+I106M (n=2)) at MOI=2
and compared to mock infected cells. Sixteen hours
post infection the cell supernatant was discarded and
the whole cell lysate was collected in NP40 lysis buffer
for the whole cell fraction, as well as fractionation into
cytoplasmic and nuclear fractions by centrifugation [64]
followed by SDS PAGE and western blotting probed for
NS1 (polyclonal rabbit serum), NP (polyclonal rabbit
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anti-histone H3, CT, pan clone A35; Millipore, Billerica,
MA, USA) and β-tubulin (mouse anti-tubulin α; Sigma,
Burlington, ON). Antibodies were detected by incubation
with HRP conjugated goat anti-rabbit or goat anti-mouse
antibody (Sigma, Burlington, ON) followed by SuperSignal
West Pico chemiluminescent substrate (Pierce, Thermo
Fisher Scientific, Nepean, ON) and exposure to X-ray film.
Human RIG-I domain binding using bacterial reverse two-
hybrid system (RTHS)
Each RTHS bacterial strain was constructed to contain
the chromosomally incorporated NS1 proteins and each
RIG-I domain (CARD, helicase and RNA binding regula-
tory domain (RD)) as previously described [35]. Using
the RTHS, two hybrid-binding results in inhibition of
selectable gene expression that inhibits replication (depicted
in Additional file 1: Figure S1). For drop spotting each
RTHS strain were grown overnight with shaking, at 37°C in
LB medium with Ampicillin (50 μg/mL) and Spectomycin
(25 μg/mL). The following day 20 μl of culture was diluted
in 10% glycerol solution and ten-fold serial dilutions pre-
pared in a sterile 96-well plate for each strain. 2.5 μl of each
dilution was drop-spotted onto selective plates (200 ml
Agar, 25 ml minimal media, 10 ml of 50% glycerol, 250 μl
1M MgSO4, 50 μg/mL Ampicillin and 25 μg/mL Spec-
tomycin), containing 25 μg/mL Kanamycin, 2.5 mM 3-
amino-1,2,4-triazole and increasing levels of IPTG (10 μM,
25 μM, 50 μM and 100 μM), which induces the expres-
sion of the target proteins. Replication was observed after
2 days and colonies counted and plotted relative to IPTG
concentration.
Microarray analysis
We used primary microarray data from infected M1 cells
compared to mock-infection with PBS for cells infected
with HK-wt as well as NS1 mutants F103L, M106I and
F103L + L106I (and M106V as another reference adap-
tive mutation at position 106 [15]) in infected M1 cells
(MOI = 2 at 8 hpi), n = 3 biological replicates and ana-
lyzed them independently here using the methods de-
scribed previously (Forbes et al. submitted). We also
analyzed human gene transcription relative to mock PBS
infected controls for the HK-wt (103F + 106M) and NS1
mutants F103L, M106I, M106V and the double F103L +
L106I mutant using A549 cells infected at MOI = 2 with
collection of total RNA at 8 hpi. At 8 hpi, the cellular RNA
was collected using manufacturer’s protocol (QIAGEN
RNeasy mini-kit) quantified using a PowerWave XS2,
Microplate Spectrophotometer (BioTek Instruments, Inc.
Winooski, VTUnited States ), and ribosomal RNA qual-
ity and integrity was confirmed using an Agilent 2100
Bioanalyzer (Agilent Technologies Canada Inc. Mississauga,
Canada). The microarray analysis was performed byStemCore Laboratories (Ottawa, Ontario, Canada) using
the Genechip Mouse Exon 1.0 ST Array and the
Genechip Human Exon 1.0 ST Array for the respective
mouse and human samples (Affymetrix, Santa Clara,
CA, USA). Genes were considered as up or down regu-
lated relative to mock infected cells if they were ≤1 or ≥1
log2 fold different (≤ or ≥ 2 fold differences) expression
level and were statistically significant at the p ≤ 0.05
level using ANOVA, and further analyzed using Bio-
conductor software packages in R for clustered heat
maps of gene expression and mutants, Pheatmaps,
(pheatmap_0.7.4.tar.gz) analyzed using the complete
linkage and Euclidian distance method; and gene ontol-
ogy, GoProfiles (goProfiles_1.20.0.tar.gz), (available at
http://bioconductor.org/biocLite.R) with outputs plot-
ted with gplots_2.11.0.tgz and user generated software.
Human and mouse genes were cross referenced using
the Human and Mouse Orthology (HUGO Gene No-
menclature Committee) file (HMD_HGNC_Accession.
rpt) obtained from the Comparative Genome Databases
(http://www.informatics.jax.org/orthology.shtml). The
microarray data have been deposited in NCBI’s Gene
Expression Omnibus [65] and are accessible through
GEO Series accession number GSE48200 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48200).
Statistical analysis
Statistical significance was measured using the student
t-test (Numbers, 09 v.2.0.4) using the parameters of
paired or equal variance and two-tailed significance
(unless otherwise indicated) with a probability of ≤ 0.05
considered as statistically significant. The Chi-squared
test was performed using GraphPad http://graphpad.com/
quickcalcs/contingency1.cfm. Values were calculated as
means +/− standard deviation for sample size > 2 and +/−
standard error for sample sizes of 2 (for some of the values
as indicated).
Genetic analysis of NS1
The amino acid sequences of NS1 from various IAV
subtypes were retrieved from the NCBI’s Influenza
Virus Resource; (www.ncbi.nlm.nih.gov/genomes/FLU/).
The frequency of the amino acid in NS1 position 103 and
106 (in reference to the A/Hong Kong/1-5-MA21/1968
strain) was calculated using the Genenious Ver 6.0.5 ana-
lysis tool.
Phylogenetic analysis
A total of 47 complete NS1 protein sequence of IAV, re-
trieved from the NCBI’s Influenza Virus Resource, were
included for the representative phylogenetic tree construc-
tion (the full tree is shown in Additional file 1: Figure S2).
Protein sequences were aligned using MUSCLE 3.7, with a
number of iterations of 12. Maximum-likelihood analysis
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WAG substitution model using 1000 bootstrap repli-
cates. GenBank accession numbers used for phylogen-
etic reconstruction can be found in supplementary
information (Additional file 1: Table S2).
Results
103L and 106I in the H5N1 NS1 gene each control
virulence in mice
To assess the virulence phenotypes associated with the
individual 103L and 106I sites the H5N1 NS-wt genome
segment that possesses the 103L and 106I mutations as
its wt reference sequence or mutants with L103F or
I106M mutations alone or in combination were rescued
into a human and mouse-adapted backbones, A/HK/1/68
(H3N2) (HK) and A/PR/8/34 (H1N1) respectively. The
relative virulence of these viruses on the HK and the
PR8 backbones were assessed in groups of 3 and 7
Swiss-Webster (CD-1) mice following intranasal infectionFigure 1 Virulence is increased by each of the 103L and 106I NS1 mu
backbones as well as for 103S and 106I PR8 NS1 gene mutations in P
with 5 × 106 pfu of rHK viruses possessing wt (103L + 106I) or mutant H5N
103 and 106. c and d. Groups of 3 CD-1 mice were infected intranasally wi
106I) or mutant H5N1 NS1 genes that differed due to the indicated mutati
infected intranasally with 1 × 104 pfu with wt rPR8 or mutants that differed
of body weight loss was calculated as the mice body weight loss was reco
shown as average +/− standard deviation (*p<0.05, **p<0.01, *** p<0.001;with 5.0 × 106 pfu and 1.0 × 104 pfu respectively. The rHK-
H5N1-NS-wt (103L+106I) and the three mutants (rHK-
H5N1-NS-L103F+106I, rHK-H5N1-NS-103L+I106M and
rHK-H5N1-NS-L103F+I106M) did not result in mortality
in CD-1 mice (all had LD50 >10
7.2 pfu) (Figure 1b). Daily
body weight monitoring showed the greatest loss for the
rHK-H5N1-NS-wt (103L+106I) virus (7% at day 5 pi).
Each of the 3 mutant caused significantly less body
weight loss on comparison of days 3–6 for H5N1-NS
mutants L103F+106I, 103L+I106M and L103F+I106M
(P≤0.01, P≤0.05, and P≤0.001 by paired t-test respect-
ively); and single time points showed significant dif-
ferences for 103L+I106M and L103F+I106M (P≤0.05
by single sample t-test, n = 3) (Figure 1a). Thus each
of the individual 103L and 106I mutations contrib-
uted to disease severity which was cumulative in
combination.
Mouse infections with 1 × 104 pfu of rPR8-H5N1-NS-wt
(wt sequence 103L+106I) resulted in 100% mortality by 8tations in the H5N1-NS gene on human and mouse adapted virus
R8 virus. a and b. Groups of 3 CD-1 mice were infected intranasally
1 NS1 genes that differed due to the indicated mutations at positions
th 1 × 104 pfu with the different rPR8 viruses possessing wt (103L +
ons at positions 103 and 106. e and f, Groups of 5 BALB/c mice were
due to the indicated mutations at positions 103 and 106. The percent
rded daily throughout the whole course of the experiment. Values are
two-tailed student’s t-test).
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Further infections of groups of mice with reduced dosages
indicated an LD50 of 10
2.8 pfu. The PR8 recombinants
possessing the single mutations, H5N1-NS-L103F+106I
and H5N1-NS-103L+I106M, had slightly reduced or de-
layed mortality (Figure 1d) associated with similar LD50
values of 103.0 and 103.6 pfu respectively, and body weight
losses similar to H5N1 NS-wt (Figure 1c). The double mu-
tant rPR8-H5N1-NS-L103F+I106M did not cause mortal-
ity, (LD50 of > 10
6.5pfu) and induced significantly less body
weight loss (maximum 4%) than H5N1 NS-wt (P ≤ 0.05
after day 3 by t-test) (Figure 1c). Therefore, each of the
103L and 106I mutations in the H5N1 NS gene was as-
sociated with enhanced disease to increase virulence
(based on reduction in LD50 relative to F103 + M106)
by >102.9 (>800) and >103.5 (>3,200) fold respectively, rela-
tive to >103.7 (>5000) fold in combination when assessed
on the mouse adapted A/PR/8/34 backbone. Thus each of
the F103L and M106I mutations resulted in similar levels
of increased virulence but this was dependent of the viru-
lence of the genetic backbone with the greatest effects
seen on a virulent virus backbone.
The properties of 103 and 106 mutations were also
studied in the context of the A/PR/8/34 (H1N1) NS
gene, that possesses 103S and 106I (considered as wt
relative to the consensus sequence of 103F and 106M),
on the same mouse adapted A/PR/8/34 backbone. The
PR8-NS1 103S and 106I sites were mutated to S103F,
I106M and S103F+I106M. The four rPR8 viruses
(rPR8-NS-103S+106I (wt), rPR8-NS-S103F+106I, rPR8-
NS-103S+I106M, rPR8-NS-S103F+I106M) were used
to infect groups of 5 BALB/c mice intranasally with
1.0×104 pfu each. The rPR8-NS-103S+106I (wt) resulted
in 100% mortality and 31% body weight loss by day 6
pi i (Figure 1e and f ), and possessed an LD50 of 10
3.5
pfu. The single NS1 S103F and I106M mutants had
small decreases in virulence and resulted in 40 % and
60% mortality; LD50 = 10
4.1 and 103.9 pfu respectively;
(Figure 1e and f ). However, both NS1 mutations
S103F+I106M in combination were avirulent at this
dose and resulted in 11% body weight loss by day 8 pi
(Figure 1e-f ), (LD50 >10
4.5 pfu). The disease severity
as indicated by body weight loss showed that each
mutation was associated with significantly less disease
than PR8-wt virus with the greatest reduction in body
weight loss associated with the I106M and a smaller
though significant effect seen for S103F mutations
(that in combination reduced severity the most) (Figure 1e)
(P values ≤ 0.05 – 0.001 by t test). Thus the analysis of
the PR8 NS1 gene on its native backbone (PR8) further
supports individual roles and cumulative effects for in-
creasing virulence for mutations at positions 103 and
106 with a greater effect seen for the 106I than the
103S mutations.NS1 103L and 106I mutations in the H5N1-NS gene
control the extent of alveolar infection in the lung
To further characterize the properties of the 103L and
106I mutations in the H5N1-NS gene on the rPR8 back-
bone the extent of mouse lung infection and tissue trop-
ism was determined by immunofluorescent staining of
frozen lung sections at 3 days post intranasal infection
with 1.0 × 105 pfu of each mutant virus. The lungs
infected with the rPR8-H5N1-NS-wt (103L+106I) virus
showed extensive virus infection and spread that en-
compassed the bronchi as well as the alveolar regions
(Figure 2b). When individually mutated back to consen-
sus, the L103F and I106M mutants showed a decrease in
the extent of alveolar tissue infection (Figure 2b-d). The
rPR8-H5N1-NS-L103F+I106M mutant was severely re-
stricted in lung infection, showing small regions of bron-
chiolar with rare foci of alveolar infection (Figure 2e).
Thus the enhanced virulence due to each of the 103L
and 106I mutations was associated with increased alveo-
lar tissue infection.
103L and 106I in H5N1-NS increase viral replication in
mouse lungs
Given that the H5N1-wt NS gene possessing 103L and
106I residues increased virulence and alveolar tropism
we then assessed virus yield in lung tissues. CD-1 mice
were infected intranasally with 5 × 103 pfu of the rPR8-
H5N1-NS-wt (103L+106I) virus as well as the three mu-
tants (L103F, I106M and L103F + I106M). Lungs from 3
mice were collected at each of days 1, 3, 5 and 7 pi and
the lung titers were determined by plaque assay. The
rPR8-H5N1-NS-wt virus grew to a high titer in CD-1
mouse lungs with a peak yield of 1.05 × 108 pfu/g at day
3 pi (Figure 3a). When each of the 103L and 106I sites
in the H5N1-NS gene was individually mutated back to
consensus, virus replication of either of the L103F and
I106M mutants was not significantly different from the
wt (103L+106I) virus (P ≥ 0.05 by single sample and
paired t-test) (Figure 3a). However when both sites were
mutated in combination, the H5N1-NS-L103F+I106M
virus possessed severely decreased viral replication (>100
fold less at day 5 pi) (P ≤ 0.01 by paired t-test from
days 1–5, n = 9) compared to the rPR8-H5N1-NS-
103L+106I, and the virus was cleared from the lungs
by day 7 pi (Figure 3a). Therefore the presence of ei-
ther one of the 103L and 106I mutations in the H5N1
NS gene resulted in a large increase in virus replication
and a delay in virus clearance in lungs.
We had shown earlier that the rPR8-H5N1-NS-
103L+106I virus suppressed IFN-β production to un-
detectable levels in M1 cells infected at an MOI = 2 at 24
hpi [13] whereas the L103F+I106M mutant generated low
but measurable levels (15 ng/ml). Measurement of the
IFN-β induced by the 2 single mutants L103F+106I and
Figure 2 103L, 106I and 103L+106I mutations in the H5N1-NS gene enhance viral tropism for alveolar tissue in mouse lungs. CD-1
mice were infected intransally with 1 × 105 pfu and lungs were collected 3 dpi. The lungs were inflated and fixed with 3.7% formaldehyde and
frozen lung sections were stained with anti-PR8 antibody. The bronchioles are indicated by an arrow. a. Mock uninfected lungs b. rPR8-H5N1-NS-
(L103 + I106) infected lungs c. rPR8-H5N1-NS-L103F + I106 infected lungs d. rPR8-H5N1-NS-L103 + I106M infected lungs e. rPR8-H5N1-NS-L103F+
I106M infected lungs.
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suppress IFN production relative to the consensus virus
that was undetectable in the case of 103L+ I106M
(Figure 3b).
We then assessed IFN-β production in vivo for the
rPR8-H5N1-NS-103L+106I (wt) and rPR8-H5N1-NS-
L103F+I106M lung homogenates. Each of these viruses
produced similar lung IFN-β levels at days 1 and 3 pi
(P ≥ 0.05, equal variance t-test) (Figure 3c). At day 5 pi
the 103L+106I mutant possessed much higher average
lung IFN-β levels than the L103F+I106M mutant (1054
pg/g versus 95 pg/g respectively) although not to a sta-
tistically significant level (which did not become signifi-
cant after increasing the number of mice to 6 per
treatment (P ≥ 0.05, t-test (n = 6)) (Figure 3c). Thus the
in vivo IFN-β production for the 103L + 106I mutant
contradicted the in vitro findings which showed re-
duced IFN induction in M1 cells (Figure 3b).
We then measured the virus yield in the M1 cell su-
pernatants analyzed for IFN-β induction in Figure 3band showed that each of the L103L and 106I mutants
demonstrated increased virus replication with the greatest
effect seen for the H5N1-NS1wt virus possessing both
103L+ 106I mutations (Figure 3d) consistent with in-
creased replication associated with increased ability to
antagonize IFN production, which paralleled the increased
replication seen for these mutants in mouse lungs
(Figure 3a).
To assess the function of these mutations independent
of the IFN response we measured virus yields in Vero
cells (that lack IFN genes) infected at moi = 0.01 with
plaque assay at 24 and 48 hpi for this set of NS1 mu-
tants. Although Vero cells are poorly permissive for PR8
replication [66], virus replication is independent of IFN
production. Each of 103L and 106I mutations signifi-
cantly decreased virus yield with an intermediate effect
for the double 103L + 106I mutant indicating that these
mutation provide an IFN independent loss of replicative
function in Vero cells. This is not inconsistent with the
enhanced IFN antagonism mediated gain-of-function
Figure 3 H5N1-NS gene 103L, 106I and 103L+106I mutations enhance viral replication in mouse lungs and increase IFN-β antagonism
in mouse cells. a. Groups of 12 CD-1 mice were infected intransally with 5x103 pfu of the rPR8-H5N1-NS and the three mutants (rPR8-H5N1-NS-
L103F, rPR8-H5N1-NS-I106M and rPR8-H5N1-NS-L103F+I106M). Lung homogenates were collected at days 1, 3, 5 and 7 pi (n = 3) and viral titers
were assessed by plaque assay. The L103F+I106M mutant generated 100 fold less virus than the others (*p<0.05; by paired two-tailed t-test).
b. IFN-β induction in mouse M1 cells. Monolayers of M1 cells in 35 mm dishes were infected at MOI = 2 and incubated for 24 h before collecting
supernatants for quantification of IFN-β by ELISA (n = 3 biological replicates with n = 2 technical replicates). The values for rPR8-H5N1-NS-wt and
NS1 L103F + I106M were first reported by [13] and are included here as controls. Values are shown as average +/− standard deviation with
significant difference indicated for NS1 L103F + I106M relate to each of the other mutants (*** p<0.001; two-tailed t-test). c. IFN-β induction in
mouse lungs. Groups of 12 CD-1 mice were infected intransally with 5x103 pfu of the rPR8-H5N1-NS and the rPR8-H5N1-NS-L103F+I106M. The
levels of IFN-β lung homogenates were determined by ELISA at days 1 and 3 (n =3), and 5 (n =6) pi. d. Infectious yield associated with IFN-β
induction in mouse M1 cells shown in panel B were quantified for infectious yield by plaque assay. The yield of the L103F+I106M mutant was
significantly less than the other 3 viruses (*** p<0.001; two-tailed t-test). e. Infectious yield in monkey Vero cells were quantified for infectious
yield by plaque assay. The yield of the L103F+I106M mutant was significantly greater than each of the other 3 viruses (*** p<0.001; two-tailed
student’s t-test).
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in mice [15].
H5N1-NS residues 103L and 106I increase NS1
cytoplasmic accumulation
The PR8 NS1 F103S and M106I mutations have been
reported to function to increase cytoplasmic localization
in MDCK cells [47] and we have seen similar results for
the F103L and M106I mutations in the HK1 NS1 gene
that resulted in increased cytoplasmic accumulation in
mouse M1 cells (N.E. Forbes et al. submitted). To deter-
mine whether the replicative gain-of-function of the
H5N1-NS1 103L+106I mutations (Figure 3d) involves al-
tered cytoplasmic accumulation the presence of NS1protein in nuclear and cytoplasmic fractions (along
with NP and M1 proteins) was assessed in mouse epi-
thelial M1 cells in vitro. Monolayers of M1 cells were
infected with the rPR8-H5N1-NS-wt (103L+106I) virus
and the three mutants (L103F+106I, 103L+I106M and
L103F+I106M) for sixteen hours before whole cell lys-
ate was collected and the nuclear as well as the cyto-
plasmic fractions were separated. Tubulin and histone
H3 were used as cytoplasmic and nuclear markers re-
spectively. The NS1 protein accumulation observed by
western blots show that the 103L and 106I NS1 residues
both functioned to increase cytoplasm abundance for the
viruses possessing the L103F+106I, 103L+I106M and
103L+106I NS1 residues relative to the L103F+ I106M
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it was primarily nuclear with greater accumulations for
the 3 viruses containing 103L and 106I mutations (relative
to L103F+I106M) whereas the M1 protein expression was
primarily cytoplasmic where the 103L+106I variant was
lowest relative to the other viruses (Figure 4a) indicating
mutation specific patterns of gene expression. Duplicate
or triplicate experiments were then analyzed to confirm
the initial NS1 accumulation observations (Figure 4b).
Interestingly, the NS1 protein cytoplasmic accumulation
was at the limit of detection for the L103F+I106M virus in
mouse M1 cells, which correlated with a significantly re-
stricted ability to replicate in vitro (Figure 3d). The single
mutants L103F+106I and 103L+I106M also enhanced the
total and nuclear NS1 protein expression 16 hpi compared
to the 103L+106I infected cells (relative to 103F+106M) in-
dicating that the 2 mutations in combination are less able
to support increased general gene expression (especially
for the M1 protein) suggesting that the gain-of-function
due to the NS1 mutations involves changed NS1 proteinFigure 4 The 103L and 106I residues in the H5N1-NS gene are associa
mouse epithelial cells. Monolayers of mouse epithelial cells were infected
NS-L103F+106I, rPR8-NS-103L+I106M and rPR8-NS-L103F+I106M (n=2) at MO
localization was detected by western blots using rabbit protein specific antibo
controls for cytoplasmic and nuclear fractions respectively. a. The nuclear and
whole cell lysate is designated as “W”, nuclear fraction as “N” and the cytoplsm
nuclear and cytoplasmic fractions in parallel for 2–3 replicates of infected M1function and or location rather than enhanced NS1 protein
synthesis (Figure 4b).
103L and 106I enhance human IFN-β transcription
inhibition but differ in binding to cleavage and
polyadenylation specificity factor 30 F2F3 domain
(CPSF30-F2F3)
The rPR8-H5N1-NS mutations 103L and 106I decreased
in vitro IFN-β production in mouse cells that correlated
with enhance infection and virulence in vivo (Figure 3).
To further understand the ability of the 103L+106I NS1
sites to affect host dependent aspects of IFN-β produc-
tion, IFN-β inhibition was examined in human cells by
assessing the effect on IFN-β promoter activation and by
assessing CPSF-30 F2F3 binding ability. Transfection
with H5N1 NS1-wt and mutant pLLB plasmids were
performed in 293T cells co-transfected with firefly lucif-
erase reporter plasmids under the control of human
IFN-β (p125) or IRF-3 (p55C1B) promoters plus an in-
ternal Renilla luciferase reference standard; followed byted with increased cytoplasmic localization of NS1 protein in
with rPR8-H5N1-NS-103L+106I (n=3) and the three mutants rPR8-
I=2 and compared to mock uninfected cells. NS1, NP and M1 proteins
dies. Rabbit anti-tubulin and mouse anti-histone antibodies were used as
cytoplasmic accumulation of NS1 protein is shown for one analysis. The
ic fraction as “C”. b. Western blots showing the H5N1-NS1 protein
cells.
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transfection. The H5N1-NS-wt gene possessing the
103L+106I residues inhibited IFN-β transcription com-
pared to the empty control pLLB vector however theFigure 5 The 103L and 106I residues in the H5N1-NS gene antagoniz
activation but differ in CPSF-30 F2F3 binding. a. H5N1-NS1 proteins (w
coupled in vitro transcription and translation of expression plasmids or emp
detection by autoradiography. Radiolabeled NS1 proteins or empty vector
pull-down using α-FLAG M2 antibody and detected by SDS-PAGE and auto
showing that the I106 mutation abrogated binding but L103 maintained b
cells in triplicate biological replicates for the H5N1-NS-wt and the three NS
dual-luciferase reporter assay. Each of the NS expression plasmids along wi
promoter as well as the renilla luciferase control pRL-SV40 reporter plasmid
IFN-β promoter activation was stimulated by poly I:C transfection. The lucif
are shown as the ratio relative to the internal renilla luciferase control. d. Th
plasmid under the control of the human IRF-3 promoter. Data represent th
two-tailed student’s t-test) of firefly luciferase activity relative to renilla.presence of the consensus amino acids 103F, 106M and
103F+106M were further reduced in IFN-β promoter
activation by significant amounts (P ≤ 0.05 by t-test)
(Figure 5c). Transcription inhibition of the IRF-3e poly I:C induced IFN-β and IRF-3 promoter transcriptional
t and mutants) as well as CPSF30-F2F3-FLAG were expressed by
ty vector in the presence of 35S labeled methionine and cysteine with
were mixed with radiolabeled CPSF30- F2F3-FLAG and subject to
radiography. b. Representative pull-down of 2 independent replicates
inding. c. IFN-β promoter activation was measured in human 293-T
mutant (L103F, I106M and L103F+I106M) expression plasmids using a
th the firefly luciferase p125 under the control of the human IFN-β
s were transfected in 293T cells. Sixteen hours following transfection,
erase activities were measured following a 24h incubation period and
e same experiment was repeated using the firefly luviferase reporter
e means of n = 3 values ± SD (*p<0.05, **p<0.01, *** p<0.001;
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(Figure 5d). The greatest IFN-β and IRF-3 transcription
inhibition was observed for the NS1 gene possessing
the 103L+106M residues.
The 103 and 106 sites map to CPSF-30 binding do-
mains [67] therefore we assessed NS1 binding to the
FLAG-F2F3 fragment of CPSF30 in the context of
H5N1-NS gene mutants. Equal expression of each NS1
protein as well as FLAG-F2F3 was verified by autoradi-
ography (Figure 5a). In the FLAG-F2F3 pull down, the
H5N1 NS1 possessing either L+I or F+I at positions
103 and 106 showed undetectable FLAG-F2F3 binding
(Figure 5b), however, the mutation I106M in the
H5N1-NS gene restored binding to FLAG-F2F3 (for
103L+I106M and L103F+I106M).
Thus we observed that the combination of NS1
103L+I106M and L103F+I106M mutations both bound to
CPSF30-F2F3 but 103L+I106M differed by enhancing
IFN-β and IRF-3 inhibition of transcription in humans
(Figure 5). However, the H5N1-NS gene (L+I) did not
bind CPSF-F2F3 (Figure 5b) and possessed the low-
est ability to inhibit human IFN-β-promoter activation
among the mutants (Figure 5a and b) but was capable
of inhibiting IFN-β induction in mouse cells to un-
detectable levels (Figure 3) indicating that IFN antag-
onism in human cells differs for this combination of
mutations.
103L and 106I H5N1-NS residues increase binding to
human RIG-I domains
A bacterial reverse two-hybrid system has been previ-
ously used to determine the strength of the protein-
protein interactions between A/WSN/1933 NS1 and the
CARD, Helicase and RD domains of human RIG-I (NS1
was found to bind RD and CARD but not the helicase
domain of RIG-I [35]). Here, we used the same system
to determine the affinity of NS1 from different IAV
strains for the domains of human RIG-I. A separate
RTHS was constructed for each protein pair; the
targeted proteins are expressed from a chromosomally-
integrated, IPTG-inducible cassette as N-terminal fusions
with 434 or P22 repressor domains (Additional file 1:
Figure S1). The interaction of the IPTG-induced pro-
teins reconstitutes a functional 434/P22 chimeric re-
pressor that prevents transcription of reporter genes
downstream. If the target proteins do not interact, a
functional repressor will not form, and the host cells
will express the reporter genes independent of IPTG
levels.
RTHS were built for the interaction of NS1 from the
H5N1 (A/HK/156/1997), H3N2 (A/HK/1/68) and H1N1
(A/Brevig Mission/1/1918) strains of influenza, with the
CARD, helicase and RD domains of RIG-I. In addition
to the wild-type NS1, residue 103 and 106 H5N1 andH3N2 mutants detailed above were also assessed by this
method, with a RTHS built for each mutant. We quanti-
fied the targeted protein-protein interaction by drop
spotting ten-fold serial dilutions of the above NS1 RTHS
strains onto selective media containing 3-amino-1, 2, 4-
triazole (2.5 mM) and kanamycin (25 μg/mL) in the
presence of increasing IPTG levels (Figure 6a). The
H5N1 data showed that the wt NS1 (103L+106I) protein
interacts strongly with CARD and RD domains of RIG-I,
but not with helicase. The L103F+106I mutant interacted
strongly with all three RIG-I domains, whereas an I106M
mutation (103L+I106M) eliminates the interaction of NS1
with RD but restored helicase binding to the helicase do-
main. Interestingly, the L103F+I106M double mutant,
with the NS1 consensus sequence, was unable to interact
with any of the RIG-I domains. These data indicated that
both the F103L and M106I mutations modulate RIG-I
binding in the H5N1 NS1 gene.
To further explore the role of point mutations in
NS1’s interaction with the domains of RIG-I, we re-
peated this experiment at 0, 5, 10, 25 and 50 μM IPTG,
for the H5N1, H3N2 and H1N1 strains. The extent of
survival of each RTHS E. coli strain was quantified via
the dilution level at which colonies survived and grew
on selective media at various IPTG levels (Figure 6b).
The RTHS titration data confirmed the above observa-
tions for the H5N1 strain (that I106M mutant does not
bind RD and L103F + I106M mutant does not bind any
of the RIG-I domains). The wt H1N1 and H3N2 NS1
proteins both bind strongly to all three domains of RIG-
I suggesting that the lack of helicase binding of WSN
NS1 may be due to laboratory adaptation. We also
tested each the 103L and M106I mutations in the H3N2
NS1 gene where the M106I mutation did not affect
binding to RIG-I domains but the F103L mutation elimi-
nated binding to helicase and RD, which were the same
binding patterns as seen for the H5N1 NS1 genes with
these amino acid combinations (Figure 6). The H3N2
F103L + M106I double mutant demonstrated binding
defects to lose the ability to bind CARD and helicase,
and showed weaker interaction with RD than wt H3N2
NS1. Interestingly, a M106V mutation, which was also
previously described to be selected on mouse adapta-
tion [15], did not affect the interaction with CARD or
helicase, but significantly weakened the interaction
with RD.
These data demonstrated that RIG-I domain binding
was positively affected by mutation at positions 103 and
106 in the avian H5N1 NS1 gene that were also subject
to epistatic affects due to NS1 gene differences between
the human HK and avian-like H5N1 NS1 proteins. Thus
IFN antagonism properties may also be affected by dif-
ferences in ability to bind the cytoplasmic RNA sensor
RIG-I.
Figure 6 (See legend on next page.)
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Figure 6 The H5N1 NS1 L103 and I106 mutations affect binding of NS1 to human RIG-I CARD, helicase and RD domains in the
bacterial reverse 2-hybrid system. a. Drop spotting of the H5N1 influenza NS1 RTHS strains on selective media. Serial dilutions (2.5 μL of each
sample containing ~10n cells/mL is indicated) of the NS1 RTHS strains (and controls), were drop spotted onto selective media containing 0, 25 or
50 μM IPTG. In the absence of IPTG, there is no expression of the targeted fusion proteins; all strains therefore grow normally (top row of plates).
Upon addition of IPTG (2nd and 3rd row of plates), the functional 434.P22 repressor will be reconstituted in those RTHS that contain interacting
proteins (Additional file 1: Figure S1), leading to cell death. The strains containing proteins that do not interact (e.g. L103F, I106M) continue to
grow normally in the presence of IPTG. b. Dose response for IPTG induction of proteins for RIGI domain binding of H5N1 and H3N2 NS1 L103
and I106 mutants as well as H1N1 and H3N2 wt NS1 proteins. RTHS constructs that possessed each of the wt H5N1 (A/HK/156/1997), H3N2
(A/HK/1/68) and H1N1 (/Brevig Mission/1/1918) or indicated 103 and 106 mutant for the H5N1 and H3N2 viruses were tested for survival under
selective medium on induction with 0, 5, 10, 25 and 50 μM IPTG. The number of surviving bacterial colonies were determined by serial dilution as
shown in panel A and plotted as bar graphs. NS1 proteins that do not bind the indicated RIG-I domain baits (CARD, helicase and RD) were not
reduced in survival relative to the non-induced controls (0 μM IPTG).
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(H3N2) NS1 gene show differential and host dependent
effects on host gene transcription in human and mouse
cells
Because RIG-I and CPSF binding are associated with
host gene regulation we performed genome-wide micro-
array analysis of mRNA abundance in human and mouse
cells relative to mock-infected control cells. Microarray
analysis was performed using the mouse Affymetrix
Genechip Mouse Exon 1.0 ST Array on RNA extracted
from mouse M1 cells 8 hours following infection with
HK-wt and NS1 mutants at a MOI of 2 that were
compared to a parallel analysis of infected human A549
cells that were analyzed using the human Affymetrix
Genechip Mouse Exon 1.0 ST Array. Three independent
infections were analyzed in parallel for each of the
infected cell types with comparisons of genes that were
significantly up or down regulated by ≥ 2 fold at the p ≤
0.05 level by ANOVA (n=3) relative to mock infected
M1 and A549 cells. The analysis included HK-wt virus
and mutants possessing F103L, M106I, and F103L +
M106I in addition to anther adaptive mutant M106V
[15]. Analysis of the transcription profile of HK-wt or
mutant infected mouse M1 cells relative to mock
infected (PBS) control cells showed 573 genes that were
greater than 2 fold up or down regulated in at least one
of the mutants (Figure 7a and d) where the F103L and
M106V induced larger effects on host gene expression
(253 and 172 up-regulated versus 184 and 269 down-
regulated genes respectively) than the wt (Figure 7d)
that had a lesser effect on host gene expression (10 up-
regulated and 0 down regulated genes) and clustered
with the M106I and F103L+M106I double mutant (19
and 40 versus 7 and 4 down-regulated respectively)
(Figure 7a and d). Thus the effect of the M106I mutant
was dominant when expressed in combination with the
L103 mutant in infected mouse cells. These gene ex-
pression patterns were independent of CPSF binding,
since all mutants had lost CPSF binding except F103L
that maintained detectable binding in the HK NS1protein (2% of HK-wt) [15] and unpublished data for
the double mutant).
In the human cells the effects on host gene expression
differed from the mouse by differentially affecting fewer
genes, that in total affected the expression of 242 genes
(Figure 7b). The HK-wt and F103L mutant had the least
effect on host gene expression with 54 and 58 up-
regulated versus 0 and 1 down-regulated genes respect-
ively (Figure 7d). These genes tended to cluster together
and were further linked with the F103L+M106I double
mutant (90 up-regulated versus 13 down-regulated genes
(Figure 7b and d)). In contrast the M106I and M106V
mutants had the greatest effect on A549 host gene ex-
pression (168 and 141 up-regulated versus 31 and 21
down-regulated genes respectively) and clustered to-
gether. The HK-wt and F103L mutant viruses that both
possessed CPSF30 binding (although reduced for F103L
in the HK NS1 [15]) had significantly less effect on
gene expression than the viruses that had lost CPSF30
binding (M106I, M106I + F103L, and M106V) by t test
(p ≤ 0.001) (Figure 7b). This was also reflected in the
number of statistically significant dysregulated genes (P ≤
0.05 by Chi-squared test) (Figure 7d). We next assessed
whether genes that were unregulated due to NS1 muta-
tions were affected in consistent patterns relative to their
expression in HK-wt infected cells. We compared the gene
expression of dysregulated genes for each of the mutants
to their expression in HK-wt infected cells (Figure 8). The
dysregulated genes had a linear relationship of relative ex-
pression to the HK-wt (Figure 8) where the increased
slope indicated the relative factor for increase in human
gene expression that was effected by each mutant (line of
best fit slopes of 3.1, 2.4, 1.5 and 1.2 for the M106I,
M106V, F103L + M106I and F103L relative to HK-wt
slope of 1) also shown with a box plot of expression levels
for each mutant (Figure 8 insert). Thus mutations that in-
creased dysregulation of host genes had a uniform effect
to modulate expression by a consistent factor.
The relative patterns of gene expression were consist-
ent with reduced host gene expression due to inhibition
Figure 7 Host gene expression is differentially affected by 103L and 106I mutation in human and mouse cells. Mouse M1 cells and
human A459 cells were wither mock infected with PBS of infected with rHK1-wt, or NS1 F103L, M106I, M106V and F103L + M106I mutants at
MOI = 2 in triplicate with extraction of total RNA at 8 hpi. Genes that were significantly increased or decreased 2 fold (≥ 21 or ≤ 2-1) by
Affymetrix microarray analysis relative to mock infected cells for any individual virus were analyzed among the viruses. Host genes are
represented in heat maps with red and blue according to with the indicated scales for the log 2 values (panels a, b and c). a) Effect of virus
infection on gene regulation in mouse M1 cells showing hierarchical cluster analysis of dys regulated genes as well as hierarchical clustering
among viruses. b) Effect of virus infection on gene regulation in human A549 cells showing hierarchical clustering of genes and viruses as
represented in panel a. Relative to HK-wt the 242 dysregulated genes were significantly upregulated for M106I, M106V and F103L + M106I
(** p ≤ 0.01, *** p ≤ 0.001 by t-test) but not F103L (not significantly different (nsd)). c) Transcriptional abundance analysis of genes that are
common between human and mouse cells were analyzed as described in panel a. d) Bar graph of up (red bars) and down (blue bars) regulated
gene transcripts detected by microarray analysis relative to mock infected M1 and A459 cells infected with the indicated viruses. The number of
significantly up and down regulated genes relative to mock infected A549 cells was significantly different for M106I, M106V and F103L + M106I
(*p ≤ 0.05 by Chi-squared test), versus HK-wt (reference, r) but not F103L that was not significantly different.
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NS1 protein binding (Figure 7b) but this pattern was not
observed in mouse cells (Figure 7a and d). The plot of
gene expression for individual genes relative to HK-wt in
mouse cells showed a similar pattern of expression forboth M106I possessing mutants but an increased pattern
of expression for F103L and M106V (Additional file 1:
Figure S3).
We also analyzed the mouse and human data together
to determine if gene regulation patterns were shared
Figure 8 Linear plot of relative gene expression of host genes between NS1 HK-wt and mutants in human A459 cells. The host gene
expression relative to HK-wt was plotted with the line of best fit for dysregulated genes in human A459 cells shown in Figure 7a. The slope of
each line is indicated relative to the HK-wt line with slope = 1. Insert. A box plot of dysregulated gens from Figure 7a shown relative to the gene
expression of HK-wt relative to mock infected M1 cells.
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genes between human and mouse (Figure 7c) with 34 and
92 genes that were unique to the mouse and human re-
spectively. In general we observed a large host-dependent
effect where genes that were differentially up or down reg-
ulated in one host (red or blue respectively) were not dif-
ferentially up or down regulated in the other host
(Figure 7c).
Characterization of genetic variation of residues 103 and
106 among NS1 proteins in nature
The prevalence of amino acid residues at position 103
and 106 was characterized for IAVes in the NCBI Influ-
enza Virus Resources database to show that the NS1
protein from avian IAVs isolated before 1980 were F/M
that were also characteristic of animal isolates or Y/M
that was characteristic of NS1 allele B which has been
maintained in a restricted subset of avian lineages. Avian
IAVs isolated after 1990, in the H1N1, H5N1 and H3N2
lineage, predominately contain the F/M residues at pos-
ition 103/106 (Figure 9), and similar observations can be
made for most other subtypes: H8N4, H7N7, H6N8,
H6N6, H6N5, H6N2, H5N3, H4N6, H4N2, H3N8,
H3N6, H3N2, H2N9, H2N3, H2N2, H1N2, H1N1, H13-
N6, H11N9, H10N7 (data not shown). In contrast, in
post-1990 H9N2 subtype viruses, the predominant res-
idue at position 103/106 is L/I found in 66% of total
isolates, therefore demonstrating positive selection of
these residues in poultry for this subtype (Figure 9). TheH6N1 lineage has also selected 103L and 106I muta-
tions that represent 31% of total H6N1 isolates in the
NCBI database (Figure 9). Although the H5N1 isolates
are predominately F/M, most of the 1997 strains are L/I,
due to reassortment with H9N2 viruses as also recently
observed for the emergent H7N9 strains [2], in addition
to the repeated independent selection of L/I residue in some
H5N1 and H9N2 viruses (Figure 9). The first human H6N1
isolate, A/Taiwan/2/2013 (H6N1) possesses the F103L mu-
tation (GISAID accession no. EPI_ISL_143275). This F103L
mutation has been selected independently of the H9N2
lineage in the Taiwanese H6N1 sublineage (data not
shown) which further links this mutation with adaptive
evolution and avian to human host switching.
Discussion
We had previously shown that the F103L+M106I muta-
tions in H5N1-NS1 conferred high virulence on the PR8
backbone. Here we show that each of the F103L and
M106I mutations in the H5N1 NS1 gene are gain-of-
function mutations that increase IFN antagonism to
overcome host resistance in the novel mouse host by in-
creasing cytoplasmic NS1 expression with possible roles
in altering RIG-I and CPSF30 host factor binding.
Mutations at F103L and M106I enhance lung infection,
replication, and virulence
Using reverse genetics and site directed mutagenesis we
show that each of the F103L and M106I mutations
Figure 9 Analysis of NS1 protein 103 and 106 residue mutation in natural human and animal isolates. a. Phylogenetic trees based on the
NS1 protein sequence of influenza A viruses isolated from subtypes H1N1, H3N2, H5N1, H6N1and H9N2. Know subtypes and amino acid at
position 103 and 106 are indicated. Different 103/106 residue motifs (FM, YM, LI) are represented by a grey square. Full trees and a list of
GenBank accession numbers of the viruses used are provided in supplementary information. Independent selection of F103L occurred in the FM
lineage and are indicated with a square (■) and independent selection of M106I is shown for 2 H9N2 isolates representative of a Middle Eastern
lineage. b. Variability found at position 103 and 106 in different IAV subtypes. H1N1, H3N2, H5N1, H6N1 and H9N2 viruses were analyzed for the
frequency of different amino acid compositions at position 103, 106 and 103/106.
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(>800 and >3,200 fold respectively, and >5,000 fold in
combination; on the basis of LD50’s of 10
3.6, 103.0, 102.8 pfu
respectively relative to the 103F + 106M mutant of >106.5
pfu)) (Figure 1). This indicated that the L103 and 106I
mutations both additively increased virulence in combin-
ation, with the greatest effect seen for the M106I mutation
(4 fold more virulent than F103L). Each of the F103L, and
M106I as well as the double F103L + M106I mutants
resulted in enhanced infection of alveoli that was associ-
ated with >100 fold increased and prolonged viral replica-
tion relative to the consensus sequence 103F+106M virus
that was attenuated and restricted to the bronchiolar in-
fection of mouse lungs (LD50 >10
6.5 pfu). This indicatedthat each of the F103L and M106I mutations overcame
barriers to lung alveolar infection but their combined ef-
fects did not further increase virus yield in vivo and thus
were both contributing to increased cytoplasmic accumu-
lation, and possibly other functions, to enhance replication
in the mouse. This is consistent with earlier studies on the
human HK virus backbone that showed that the 106I mu-
tation caused the largest loss in body weight (20%), among
8 single nucleotide adaptive mutants, and the F103L mu-
tant induced a lesser weight loss of 10% [15].
Cytoplasmic accumulation
Each of the 103L and 106I mutations increased cytoplas-
mic accumulation of the H5N1 NS1 protein that would
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Both of these mutations have been shown to enhance
cytoplasmic accumulation when introduced into the A/
HK/1/68 (H3N2) backbone, (Forbes et al. submitted). In-
corporation of 103L or 106I mutation may activate or
enhance a secondary nuclear export function, in addition
to the originally indentified NES at position 137-148
[68], to enhance interactions with exportin molecules or
other parts of the nuclear pore complex [69,70]. Further
support for this conclusion is that the 103S and 106I
NS1 mutations in PR8 (H1N1) and A/Sydney/5/97
(H3N2) control cytoplasmic versus nuclear localization
in transfected MDCK cells [47]. The M106I mutation
has also been shown to restore a defect in cytoplasmic
localization and IFN antagonism of the 2003 lineage
avian H5N1 NS1 gene in human A549 cells [71]. Muta-
tions that result in increased binding to nuclear or cyto-
plasmic factors may also affect cellular trafficking by
tethering NS1 protein to host proteins in specific loca-
tions such as cytoplasmic RIG-I and nuclear CPSF30 as
shown for other proteins [69,72]. The biochemical basis
for increased cytoplasmic localization could involve re-
duced binding to nuclear localized CPSF30; however the
CPSF30 binding mutant 103F also trafficked to the cyto-
plasm arguing against CPSF30 binding playing a major
role in nuclear sequestration of NS1 protein (Figure 4).
But the fact that H5N1 NS1 103L mutant binds CPSF
may account for its greater ability to inhibit expression
from the IFN promoter, relative to the 106I mutant that
did not bind CPSF.
Effects of F103L and M106I on host gene transcription
The F103L and M106I mutations differed in their effects
on host gene transcription where in mouse cells the
103L induced a large host gene regulation phenotype
versus 106I that had a very small effect on host gene
regulation that was dominant in combination in the
double mutant. The numbers of deregulated host genes
at 8 hpi for HK-wt (H3N2) in M1 cells were comparable
to that published for mouse lungs infected with wt or
mouse adapted A/Aichi/2/1968 (H3N2) at 12 hpi with 36
or 22 dysreguated genes respectively [73]. This pattern
of host gene regulation was host dependent and was re-
versed for the F103L and M106I single mutations in the
human cells but again the low effect, in this case of the
F103L mutation, was dominant in the F103L + M106I
combination. The numbers of dysregulated genes due to
HK-wt infection were comparable to that published for
seasonal and pandemic H1N1 strains at 8 hpi in A549
cells (with 44 and 49 differentially regulated genes re-
spectively) [74] or for HPAI H5N1 or H5N1 cold adapted
vaccine (24 and 128 genes respectively) at 8 hpi [75]. The
reduced effect on host gene expression by the HK-wt and
F103L mutant was consistent with the maintenance ofCPSF binding for these viruses in human cells and is sup-
ported by decreased host gene expression due to NS1 pro-
tein expression in human cell culture [76]. So in both
human and mouse cells the double mutant was associated
with a low effect on host gene regulation and was inde-
pendent of CPSF binding in mouse cells but correlated
with CPSF binding in human cells, suggesting that this
pair of mutations may have modulating effects on host
gene dysregulation in alternative hosts. Although we have
not extended our analysis to the characterization of indi-
vidual genes, only 3 genes were highly up regulated in
both hosts for HK-wt and mutants that included IFN in-
duced genes with tetratricopeptide repeats IFIT1 gi: 3434,
IFIT1B gi: 439996, and IFIT2 gi: 3433 in addition to the
ubiquitin peptidase USP41 gi: 373856. Both hosts also
shared 2 genes that were down regulated to the greatest
extent among HK-wt and all mutants; Mphosph6, M
phase phosphoprotein 6 gi: 68533 involved in ribosomal
RNA processing and Cdkn2aip CDKN2A interacting pro-
tein gi: 70925 involved in cell cycle regulation.
Enhanced IFN antagonism and disease
In addition to human cells, each mutation also increased
IFN antagonism in vitro in mouse cells to decrease IFN-
β induction; 103L was more effective than 106I in this
regard, reducing IFN to undetectable levels when pres-
ent alone or in combination (with 106I) suggesting that
the 103L mutation may provide a dominant ability to
antagonize the IFN response (that supplements the in-
complete ability of 106I to antagonize IFN induction)
(Figure 3). Although the double 103L + 106I mutant did
not induce IFN in mouse cells, it induced the same
amount of IFN-β in mouse lungs as the consensus
H5N1-NS1 103F+106M mutant that was attenuated
due to the restriction of infection to bronchiolar tissues
(Figure 2). The data is consistent with a model where
H5N1-NS1 103F+106M virus infects the bronchiolar
epithelium in the lung but induced inhibitory level of
IFN that prevented alveolar infection and limited peak
titers to 105 pfu/g in contrast to the 103L+106I variant
that produced 108 pfu/g at 3 dpi in the lung due to the
spread of infection to the alveoli in the presence of the
same levels of IFN-β at 1 and 3 dpi (Figure 2). However
the NS1 consensus sequence mutant, 103F+106M, was
inhibited from further replication by the induced IFN-β
and was cleared by day 7 in contrast to 103L+106I that
continued to replicate, due to increased NS1 cytoplas-
mic abundance and/or activity, but that continues to
induce IFN-β with an average yield of 1054 pg/g at
5 dpi (Figure 2). Thus lethal pathology at these doses
may have been a function of extensive tissue infection
(Figure 2 and 3) and high cytokine induction to induce
hypercytokinemia of IFN-β that approximated the mouse
LD50 intramuscular dose for type I IFN of 1,300 pg/g [77]
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that may contribute to the lethality associated with the
103L+106I induced pneumonia (Figures 1, 2 and 3). Al-
though the in vivo data of enhanced IFN-β induction in
the mouse lung (Figure 3b) appears to contradict the
reduced IFN-β induction seen in mouse cells seen in
Figure 3b, these findings are however consistent with
the low level of human IFN-β induced by A/HK/156/
1997 (H5N1) virus on infection of human A549 epithe-
lium [78] versus the high IFN-β seen in humans
infected with H5N1 viruses [79]. This may be due to
the fact that other cell types are infected in the lung
that induce high amount of IFN, such as shown for sev-
eral H5N1 strains or their NS1 genes expressed in A/
WSN/1933 (H1N1) reassortants that induced higher
levels of cytokines including IFN-β [80]. Thus the high
IFN-β levels produced in mouse lungs infected with the
H5N1 NS1-wt virus may be due to the infection of other
cell types in addition to epithelium in mouse lung such as
immune cells including macrophages (Figure 3c). Thus
IFN antagonism in vitro and in vivo may differ due to the
extent of infection and the types of cells that are infected.
However, further analysis of the roles of individual cell
types in the infected mouse lung are required to explain
the differences in IFN responses and pathology.
Epistasis in NS1
We have previously shown that each of the F103L and
M106I NS1 mutations in the HK virus increase virulence
in the mouse without increasing IFN induction [15].
Further analysis of these mutations in the same HK1
NS1 gene but on the PR8 backbone showed increased
virulence for each of the F103L and M106I mutations
however virulence was not further increased in combin-
ation due to increased IFN-β production [13]. However
we have shown here (Figure 3) and previously [13,15]
that the IFN antagonism phenotypes of the 103L and
106I mutations are dependent on each other as well as
the NS1 gene and virus backbones indicating that these
mutations are subject to epistasis. However the F103L
and M106I mutations in the H5N1 NS1 gene on the
PR8 backbone resulted in gain-of-function seen as in-
creased replication, virulence and IFN antagonism ([13],
Figures 1, 2 and 3) indicating that the H5N1 NS1 gene
possessed mutations that control the negative epistatic
effects of this pair of mutations on the PR8 backbone
[13]. This negatives epistasis may explain the previous
observation of the A/HK/483/1997 (H5N1) virus that
possesses the 103L+106I mutations and has extreme
virulence for mice with of LD50 = 10 pfu whereas the
L103F+I106M mutant had increased in virulence to re-
sult in LD50 = 0.032 pfu (the effect of each of the L103F
or I106M mutations in isolation was not assessed), how-
ever the lethality of infectious dosages that are less than1 suggests that the infectivity assays underestimated true
mouse infectivity, thus complicating interpretation of
these findings [16]. Epistasis may similarly explain the
lack of effect of the 103S + 106I mutations on virulence
when mutated back to consensus (S103F + I106M) in
the hypervirulent variant of PR8 (hvPR8) virus in BALB/
c mice (but with a 6 fold increase of virulence seen in
MX1 mice) however the effect of each mutation in isola-
tion was not assessed [81]. This is in contrast to the
gain-of-function that the103S and 106I mutations pro-
vided in the standard PR8 strain (Figure 1e and f). The
F103L + M106I mutations had originally been associated
with increased IFN-β induction that correlated with a
loss of CPSF binding by the H5N1 NS1 [67] however
this phenotype is not seen for the 103S and 106I muta-
tions of hvPR8 that similarly abrogates CPSF binding
but without affecting IFN-β induction [81] indicating
that the genetic context of these mutations is critical for
their IFN antagonism phenotypes. Our observed IFN in-
dependent loss of function due to the 103L and 103I
mutations in Vero cells was consistent with the afore-
mentioned studies; however these mutations functioned
to enhance IFN antagonism in IFN competent systems
(Figures 3, 4 and 6) as well as [13,15].
Human RIG-I binding
We also observed that RIG-I domain binding of the
avian-type H5N1 NS1 protein possessing the consensus
103F+106M residues was defective and did not bind any
domains, but the single 106I mutation restored binding
to all 3 domains (CARD, helicase and RD) and 103L re-
stored binding to 2 domains (CARD and helicase) and
the combination bound 2 different domains (CARD and
RD) (Figure 6). Thus the restoration of human RIG-I
binding by the 103L and 106I mutations may contribute
to the ability of the 1997 H5N1 viruses to infect humans
[79,82]. We have not yet assessed the effect of these mu-
tations on mouse RIG-I binding and further studies are
needed to assess the role of RIG-I binding in modulating
IFN antagonism in human and mouse cells in addition
to the roles for TRIM25 and RIPLET binding in mouse
adaptation [34]. In addition to the demonstration that
F103L and M106I mutations are under positive selection
for human IAV H3N2 in the mouse, they were also inde-
pendently selected in avian H9N2 and H6N1 lineages in
Asia. Significantly these mutant NS1 genes can transfer
to additional subtypes by reassortment, including H5N1,
H6N1 and H7N9 viruses, which can infect multiple
avian species and transmit to humans illustrating the po-
tential for these mutations to promote host switching
among multiple species (Figure 9). We demonstrate that
both of these mutations provide gain-of-function to in-
creased cytoplasmic expression and possibly altered host
factor function to enhance interferon antagonism. These
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interstitial pneumonia by mediating the productive in-
fection of alveolar tissue which provides a model for
examining enhanced infection and disease of avian 1997
H5N1 and H7N9 viruses in humans that are likewise as-
sociated with severe interstitial pneumonia with associ-
ated cytokinemia [5,6] (as also seen in the mouse model
(Figures 1, 2 and 3)). The first human H6N1 influenza
infection possessed the NS1 F103L mutation further
linking this mutation with host switching.
Conclusion
We hypothesize that 103L and 106I increased the IFN
antagonism properties of H5N1 NS1 in mice by increas-
ing the expression and trafficking of NS1 into the cyto-
plasm as well as increased host factor binding such as
RIG-I to mediate enhanced functional interactions with
the IFN sensing and IFN effecter functions of the host.
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